The chemical name of Degronin is nifedipine extended-release tablets, which belongs to a kind of antihypertensive drugs, belongs to calcium antagonists, mainly through hindering the inward flow of calcium ions in the myocardium and vascular smooth muscle, causing a decrease in the contractility of the myocardium and vasodilation, to achieve the purpose of controlling blood pressure. The possible adverse reactions found in clinical use are: i. Liver, occasionally jaundice can occur. Second, the circulatory system, mainly manifested as chest pain, headache, flushing, blurred eyes, palpitation, hypotension, lower limb edema, mainly manifested as edema of the ankle of both lower limbs. Third, allergic reaction, occasional skin rash, itching and so on. Fourth, the digestive system, can appear abdominal pain, nausea, loss of appetite. Fifth, long-term application may have gingival hyperplasia in some patients. Sixth, metabolic abnormalities, in some patients may appear high blood sugar symptoms. Overall, it is a well-tolerated antihypertensive drug with fewer adverse effects if used under medical supervision.